Showing results (2181-2190 of 2,492) with videos related to

Sort By:
Pageof 250
European Journal of Endocrinology|August 13, 2013
Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver diseaseS Döcke, J F Lock, A L Birkenfeld, et al.
JTO Clinical and Research Reports|July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 TrialBenjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
Journal of Clinical Medicine|June 28, 2023
Is the Standard Artificial Urinary Sphincter AMS 800 Still a Treatment Option for the Irradiated Male Patient Presenting with a Devastated Bladder Outlet?Fabian Queissert, Tanja Huesch, Alexander Kretschmer, et al.
Leukemia|December 22, 2018
Combination of flow cytometry and functional imaging for monitoring of residual disease in myelomaL Rasche, D Alapat, M Kumar, et al.
Nature Human Behaviour|May 14, 2021
Biodiversity conservation as a promising frontier for behavioural scienceKristian Steensen Nielsen, Theresa M Marteau, Jan M Bauer, et al.
JCO Precision Oncology|October 5, 2020
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA AssayKatherine Clifton, Thereasa A Rich, Christine Parseghian, et al.
Contemporary Clinical Trials|November 4, 2019
Study to promote innovation in rural integrated telepsychiatry (SPIRIT): Rationale and design of a randomized comparative effectiveness trial of managing complex psychiatric disorders in rural primary care clinicsJohn C Fortney, Patrick J Heagerty, Amy M Bauer, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
Nature Communications|August 18, 2017
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencingL Rasche, S S Chavan, O W Stephens, et al.
The Lancet. Oncology|September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trialAung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Pageof 250